Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Merrimack Pharmaceuticals Inc    MACK

MERRIMACK PHARMACEUTICALS INC (MACK)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/11/2018 06/12/2018 06/13/2018 06/14/2018 06/15/2018 Date
8.89(c) 8.79(c) 9.67(c) 9.02(c) 9.08(c) Last
159 722 69 516 1 267 236 241 097 187 806 Volume
-3.47% -1.12% +10.01% -6.72% +0.67% Change
More quotes
Financials (USD)
Sales 2018 -
EBIT 2018 -75,7 M
Net income 2018 -73,7 M
Finance 2018 158 M
Yield 2018 -
Sales 2019 -
EBIT 2019 -86,3 M
Net income 2019 -84,8 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 0
Capitalization 121 M
More Financials
Company
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer.Its pipeline includes MM-131, MM-141, and MM-310.The company... 
More about the company
Surperformance© ratings of Merrimack Pharmaceuticals
Trading Rating : Investor Rating : -
More Ratings
Latest news on MERRIMACK PHARMACEUTICALS
06/15MERRIMACK PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Hold..
AQ
06/07MERRIMACK PHARMACEUTICALS : to Present at the 2018 American Society of Clinical ..
AQ
05/29MERRIMACK PHARMACEUTICALS : to Present at the 2018 American Society of Clinical ..
PU
05/25MERRIMACK PHARMACEUTICALS : Patent Issued for Compositions and Methods for Non-I..
AQ
05/14MERRIMACK PHARMACEUTICALS : Reports First Quarter 2018 Financial Results
AQ
05/08MERRIMACK PHARMACEUTICALS : Management's Discussion and Analysis of Financial Co..
AQ
05/08MERRIMACK PHARMACEUTICALS INC : Results of Operations and Financial Condition, F..
AQ
05/08MERRIMACK PHARMACEUTICALS : Reports First Quarter 2018 Financial Results
PU
05/07MERRIMACK PHARMACEUTICALS : Announces Timing of first quarter 2018 Investor Conf..
AQ
05/01MERRIMACK PHARMACEUTICALS : Announces Timing of First Quarter 2018 Investor Conf..
PR
More news
Sector news : Biotechnology & Medical Research - NEC
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/01Lilly, Incyte Get FDA OK for Lower-Dose Rheumatoid Arthritis Drug
DJ
05/30Gap in regulating biotech drug copies prompts WHO to step in
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
06/15$MACK New Form 4 for Merrimack Pharmaceuticals From our Stock News Alerts App 
06/15$MACK New Form 8-K for Merrimack Pharmaceuticals From our Stock News Alerts A.. 
06/14Merrimack Pharmaceuticals $MACK Sees Strong Trading Volume  
06/13Merrimack Pharma breaks free of consolidation, up 10%  
06/13TREND REVERSAL UP ALERT: $MACK MERRIMACK PHARMACEUTICALS ? TradeIdeas via  
More tweets
Qtime:27
News from SeekingAlpha
06/16A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals 
06/13Merrimack Pharma breaks free of consolidation, up 10% 
05/08Merrimack Pharmaceuticals' (MACK) CEO Richard Peters on Q1 2018 Results - Ear.. 
05/08Merrimack Pharmaceuticals misses by $0.17 
04/19Merrimack Pharmaceuticals Potential Catalyst A Likely Bust 
Chart MERRIMACK PHARMACEUTICALS
Duration : Period :
Merrimack Pharmaceuticals  Technical Analysis Chart | MACK | US5903282094 | 4-Traders
Technical analysis trends MERRIMACK PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 13,0 $
Spread / Average Target 43%
EPS Revisions
Managers
NameTitle
Richard Peters President, Chief Executive Officer & Director
Gary L. Crocker Chairman
Jeffrey A. Munsie Secretary, Head-Operations & General Counsel
Jean M. Franchi CFO, Treasurer & Principal Accounting Officer
Sergio L. Santillana Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MERRIMACK PHARMACEUTICALS INC-11.41%121
CELLTRION, INC.--.--%33 987
IQVIA HOLDINGS INC5.50%21 394
LONZA GROUP3.38%20 341
INCYTE CORPORATION-21.91%15 677
ALNYLAM PHARMACEUTICALS, INC.-15.15%10 836